Company Profile
Acumen Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- ABOS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.19 USD (-0.57%)
Close
Last updated: November 19, 2026
171M USD
Market cap
Why the stock is moving
As of Nov 19, 2026, ABOS closed down 0.57% at $0.1933. No new same-company headline was identified in the current news window.
Company overview
Alzheimer’s Disease Antibody Company
Acumen Pharmaceuticals develops therapies targeting soluble amyloid-beta oligomers, which are believed to contribute directly to synaptic dysfunction in Alzheimer’s disease.
Sabirnetug
Sabirnetug is a monoclonal antibody designed to selectively bind toxic amyloid-beta oligomers while limiting interaction with monomers and plaques.
Enhanced Brain Delivery
Acumen is also developing an enhanced brain-delivery platform intended to improve central nervous system exposure of future biologics.
ALTITUDE-AD Clinical Program
The Phase 2 ALTITUDE-AD study evaluates two intravenous doses of sabirnetug against placebo over 18 months in early Alzheimer's disease. The trial measures integrated cognitive and functional outcomes together with safety and biomarker endpoints.
Future catalysts
- Topline results from the Phase 2 ALTITUDE-AD study of sabirnetug in November 2026.
- IND submission for the lead Enhanced Brain Delivery candidate in mid-2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Acumen Pharmaceuticals (ABOS)?
Acumen Pharmaceuticals (ABOS) most recently closed at 0.19 USD, a -0.57% move versus the previous session.
What is the market cap of Acumen Pharmaceuticals (ABOS)?
Acumen Pharmaceuticals currently has a market capitalization of 171M USD on BioPharmSignal.
What does Acumen Pharmaceuticals do?
Alzheimer’s Disease Antibody Company Acumen Pharmaceuticals develops therapies targeting soluble amyloid-beta oligomers, which are believed to contribute directly to synaptic dysfunction in Alzheimer’s disease. Sabirnetug Sabirnetug is a monoclonal antibody designed to selectively bind toxic amyloid-beta oligomers while limiting interaction with monomers...
On which exchange is ABOS stock listed?
Acumen Pharmaceuticals (ABOS) is associated with NASDAQ, United States, Biopharma.
What is ALTITUDE-AD?
Topline results from the Phase 2 ALTITUDE-AD study of sabirnetug in November 2026.
Which conditions is Acumen Pharmaceuticals targeting with ALTITUDE-AD?
Topline results from the Phase 2 ALTITUDE-AD study of sabirnetug in November 2026.
How does Acumen Pharmaceuticals describe recent progress with ALTITUDE-AD?
Topline results from the Phase 2 ALTITUDE-AD study of sabirnetug in November 2026.
What is Alzheimer?
Alzheimer’s Disease Antibody Company Acumen Pharmaceuticals develops therapies targeting soluble amyloid-beta oligomers, which are believed to contribute directly to synaptic dysfunction in Alzheimer’s disease.
